“…First, our data further support the recommendation of international guidelines to consider TT administration immediately after progression to the first line; second, from a clinical perspective, we provide support to physicians in the therapeutic decision-making after PD to TT in pMMR/MSS tumors, highlighting that combinatory regimens plus anti-VEGF are the preferred strategy when feasible; third, the description of real-world attrition rates and efficacy data after TT in patients with BRAF V600E -mutated mCRC may be helpful in the design of clinical trials focused on the continuum-of-care of this specific molecular subgroup of patients, including rechallenge strategies. 29 …”